- Home
- ATLN vs MGNX Comparison
ATLN vs MGNX Comparison
Compare ATLN & MGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATLN
- MGNX
- Stock Information
- Founded
- ATLN N/A
- MGNX 2000
- Country
- ATLN
- MGNX United States
- Employees
- ATLN 7
- MGNX N/A
- Industry
- ATLN
- MGNX Biotechnology: Pharmaceutical Preparations
- Sector
- ATLN
- MGNX Health Care
- Exchange
- ATLN NYSE
- MGNX Nasdaq
- Market Cap
- ATLN 248.2M
- MGNX 257.3M
- IPO Year
- ATLN N/A
- MGNX 2013
- Fundamental
- Price
- ATLN $5.65
- MGNX $3.00
- Analyst Decision
- ATLN
- MGNX Hold
- Analyst Count
- ATLN 0
- MGNX 10
- Target Price
- ATLN N/A
- MGNX $7.17
- AVG Volume (30 Days)
- ATLN N/A
- MGNX 496.5K
- Earning Date
- ATLN N/A
- MGNX 03-06-2025
- Dividend Yield
- ATLN N/A
- MGNX N/A
- EPS Growth
- ATLN N/A
- MGNX N/A
- EPS
- ATLN N/A
- MGNX N/A
- Revenue
- ATLN N/A
- MGNX $141,329,000.00
- Revenue This Year
- ATLN N/A
- MGNX $174.73
- Revenue Next Year
- ATLN N/A
- MGNX N/A
- P/E Ratio
- ATLN N/A
- MGNX N/A
- Revenue Growth
- ATLN N/A
- MGNX 16.68
- 52 Week Low
- ATLN N/A
- MGNX $2.95
- 52 Week High
- ATLN N/A
- MGNX $21.88
- Technical
- Relative Strength Index (RSI)
- ATLN N/A
- MGNX 37.54
- Support Level
- ATLN N/A
- MGNX $3.00
- Resistance Level
- ATLN N/A
- MGNX $3.22
- Average True Range (ATR)
- ATLN 0.00
- MGNX 0.17
- MACD
- ATLN 0.00
- MGNX -0.02
- Stochastic Oscillator
- ATLN 0.00
- MGNX 7.69
About ATLN ATLANTIC INTERNATIONAL CORP
Atlantic International Corp formerly SeqLL Inc is a technology company providing life sciences instrumentation and research services in collaborative partnerships aimed at the development of novel scientific assets and intellectual property across multiple omics fields. The company leverages its expertise with the True Single Molecule Sequencing platform to empower scientists and researchers with improved genetic tools to greater understand the molecular mechanisms of disease that is essential to the continued development of new breakthroughs in genomic medicine, and that hopefully address the critical concerns involved with precision medicine.
About MGNX MacroGenics Inc.
Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. Its pipeline MGC018 (B7-H3), Lorigerlimab (PD-1 x CTLA-4), Tebotelimab (PD-1 x LAG-3), MGD024 (CD123 x CD3), IMGC936 (ADAM9), Enoblituzumab (anti-B7-H3), Retifanlimab (PD-1), and MGD014 (HIV x CD3).